Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China · Delayed Price · Currency is CNY 30.06
+0.22 (0.74%)
Jun 1, 2026, 3:00 PM CST
SHA:688076 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 325.41 | 404.39 | 162.94 | 129.11 | 115.39 |
Depreciation & Amortization | 317.94 | 209.29 | 135.55 | 99.96 | 84.77 |
Other Amortization | 11.35 | 7.73 | 4.61 | 4.72 | 4.25 |
Loss (Gain) From Sale of Assets | 0.01 | -0.5 | -0.18 | -18.89 | -0.06 |
Asset Writedown & Restructuring Costs | 85.03 | 9.7 | 15.3 | 0.45 | 2.31 |
Loss (Gain) From Sale of Investments | -2.03 | 1.72 | -3.16 | -19.98 | -3.22 |
Provision & Write-off of Bad Debts | - | 20.62 | 5.11 | 5.87 | 1.65 |
Other Operating Activities | 69.34 | 58.16 | 49 | 29.63 | 15.44 |
Change in Accounts Receivable | 68.38 | -348.97 | -126.49 | -145.04 | -45.88 |
Change in Inventory | -398.23 | -243.29 | -82.58 | -111.74 | -87.63 |
Change in Accounts Payable | 243.1 | 291.17 | 180.38 | 58.34 | 75.82 |
Change in Other Net Operating Assets | 4.66 | 32.63 | 23.3 | 1.71 | 8.77 |
Operating Cash Flow | 681.24 | 400.12 | 350.21 | 29.29 | 180.75 |
Operating Cash Flow Growth | 70.26% | 14.25% | 1095.59% | -83.79% | 27.84% |
Capital Expenditures | -1,367 | -1,090 | -660.64 | -438.36 | -233.36 |
Sale of Property, Plant & Equipment | 1.27 | 3.98 | 1.53 | 0.06 | 0.34 |
Divestitures | - | - | - | 13.12 | - |
Investment in Securities | 64.81 | -308 | -6 | -25.95 | -7 |
Other Investing Activities | 1.85 | 0.95 | 2.9 | 1.39 | 3.09 |
Investing Cash Flow | -1,299 | -1,393 | -662.21 | -449.74 | -236.93 |
Short-Term Debt Issued | - | - | - | - | 242.68 |
Long-Term Debt Issued | 2,504 | 1,698 | 1,146 | 388.99 | - |
Total Debt Issued | 2,504 | 1,698 | 1,146 | 388.99 | 242.68 |
Short-Term Debt Repaid | - | - | - | - | -422.79 |
Long-Term Debt Repaid | -1,354 | -901.76 | -454.73 | -129.65 | -4.11 |
Total Debt Repaid | -1,354 | -901.76 | -454.73 | -129.65 | -426.91 |
Net Debt Issued (Repaid) | 1,150 | 796.43 | 691.05 | 259.34 | -184.23 |
Issuance of Common Stock | 12.53 | 22.98 | - | - | 762.63 |
Common Dividends Paid | -239.6 | -118.75 | -57.61 | -40.57 | -6.04 |
Dividends Paid | -239.6 | -118.75 | -57.61 | -40.57 | -6.04 |
Other Financing Activities | 3.46 | 99.1 | -1.54 | 18.15 | -37.47 |
Financing Cash Flow | 926.37 | 799.75 | 631.9 | 236.91 | 534.89 |
Foreign Exchange Rate Adjustments | 0.92 | 8.34 | -3.21 | -0.82 | -1.58 |
Net Cash Flow | 309.45 | -184.98 | 316.69 | -184.35 | 477.13 |
Free Cash Flow | -685.77 | -690.01 | -310.43 | -409.07 | -52.61 |
Free Cash Flow Margin | -35.30% | -42.47% | -30.04% | -62.81% | -8.17% |
Free Cash Flow Per Share | -2.19 | -2.24 | -1.03 | -1.38 | -0.20 |
Cash Income Tax Paid | -34.21 | 18.56 | 8.2 | -29.3 | -11.18 |
Levered Free Cash Flow | -675.67 | -856.88 | -374.23 | -441.9 | -133.86 |
Unlevered Free Cash Flow | -675.67 | -835.17 | -364.18 | -436.11 | -130.04 |
Change in Working Capital | -125.8 | -311 | -18.95 | -201.59 | -39.78 |